Sofinnova Partners

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Latent Labs is a pioneering AI laboratory specializing in programmable biology. It develops advanced generative AI models that capture the core principles of biology, empowering healthcare partners to create novel antibodies, optimize existing enzymes, and advance genetic engineering. This enables partners to gain unparalleled control over molecular biology, driving transformative advancements in health and sustainability.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Cure51 is a company focused on advancing cancer treatment through the development of a clinical and molecular database. Its primary mission is to create a comprehensive database of cancer survivors, utilizing their unique biological characteristics to identify potential drug targets. By analyzing the biology of long-term cancer survivors, Cure51 aims to aid healthcare researchers in decoding genetic information derived from biopsies, blood tests, imaging, and other samples. This innovative approach seeks to accelerate drug discovery, ultimately contributing to the formulation of new and effective cancer therapies.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

DISCO Pharmaceuticals is a biotechnology company focused on advancing cancer treatment through its innovative surfaceome mapping platform. The firm specializes in large-scale surfaceome unlocking of cancer cells, utilizing transformative cell discovery technology to identify proteins and protein communities present on the surface of cancer cells. This scalable approach allows for the extraction of comprehensive target information that traditional proteomics, genome, or transcriptome sequencing methods cannot provide. By leveraging this technology, DISCO Pharmaceuticals aims to enable the development of cancer-selective therapies, potentially enhancing treatment efficacy while minimizing side effects for patients.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Founded in Seattle in 2008, Arzeda specializes in protein design technology. It creates and manufactures proteins and enzymes for pharmaceuticals, industrial chemicals, polymers, and other advanced applications.

Betteromics is a SaaS platform empowering life sciences professionals with AI-driven computational techniques. It integrates seamlessly within clients' Virtual Private Clouds, connecting diverse data sources and providing a centralized, objective data hub. The platform accelerates precision biomarker discovery and clinical research by managing large, complex molecular datasets securely.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

EnginZyme is a Swedish biotechnology company established in 2014. It specializes in sustainable biomanufacturing, providing green chemistry solutions to various industries such as pharmaceuticals, food, chemicals, flavors, and fragrances. The company's patented cell-free technology platform enables the production of sustainable alternatives to plastics, nylons, rubbers, and other synthetics.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in the development of bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on engineering microbial hosts to produce a range of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. DMC Biotechnologies employs its proprietary Dynamic Metabolic Control technology to enhance production efficiency, thereby reducing costs and accelerating the timeline from discovery to commercial performance. The company's innovative approach supports sustainability by utilizing lower energy and resource inputs in the manufacturing process.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

Home Biosciences is a European venture builder and accelerator focused on biotechnology, based in Paris, France, and founded in 2019.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers unique products and collaborative research and development services that aid in the discovery of new cell strains and molecules. Its cell analysis systems facilitate the screening and isolation of rare and valuable biological variants, catering to various applications in research, therapeutic development, bioproduction, and diagnostics. By streamlining these processes, Sphere Fluidics enables clients to reduce costs and time, thereby accelerating advancements in biological and biopharmaceutical discovery.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Mnemo Therapeutics is a biotechnology company developing immune-based therapies, including cell therapies. Its EnfiniT platform uses epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes across various cancers.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

EnginZyme is a Swedish biotechnology company established in 2014. It specializes in sustainable biomanufacturing, providing green chemistry solutions to various industries such as pharmaceuticals, food, chemicals, flavors, and fragrances. The company's patented cell-free technology platform enables the production of sustainable alternatives to plastics, nylons, rubbers, and other synthetics.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in the development of bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on engineering microbial hosts to produce a range of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. DMC Biotechnologies employs its proprietary Dynamic Metabolic Control technology to enhance production efficiency, thereby reducing costs and accelerating the timeline from discovery to commercial performance. The company's innovative approach supports sustainability by utilizing lower energy and resource inputs in the manufacturing process.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

ProQR Therapeutics is a biopharmaceutical company focused on developing RNA-based therapies for patients with severe genetic rare diseases. Its primary focus includes Leber's congenital amaurosis type 10, dystrophic epidermolysis bullosa, and other inherited retinal disorders.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

ProQR Therapeutics is a biopharmaceutical company focused on developing RNA-based therapies for patients with severe genetic rare diseases. Its primary focus includes Leber's congenital amaurosis type 10, dystrophic epidermolysis bullosa, and other inherited retinal disorders.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines targeting bacterial infections. Established in 2004, the company employs recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules that demonstrate high consistency and reproducibility across batches. This technology is instrumental in creating new prophylactic and therapeutic vaccines, contributing to the prevention and treatment of bacterial infections. As of February 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines targeting bacterial infections. Established in 2004, the company employs recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules that demonstrate high consistency and reproducibility across batches. This technology is instrumental in creating new prophylactic and therapeutic vaccines, contributing to the prevention and treatment of bacterial infections. As of February 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.